<info type="ChemicalEntity">Pethidine</info>-associated <info type="DiseaseOrPhenotypicFeature">seizure</info> in a healthy <info type="OrganismTaxon">adolescent</info> receiving <info type="ChemicalEntity">pethidine</info> for <info type="DiseaseOrPhenotypicFeature">postoperative pain</info> control.

A healthy <info type="OrganismTaxon">17-year-old male</info> received standard intermittent doses of <info type="ChemicalEntity">pethidine</info> via a patient-controlled analgesia (PCA) pump for management of <info type="DiseaseOrPhenotypicFeature">postoperative pain</info> control. Twenty-three h postoperatively he developed a brief self-limited <info type="DiseaseOrPhenotypicFeature">seizure</info>. Both plasma <info type="ChemicalEntity">pethidine</info> and <info type="ChemicalEntity">norpethidine</info> were elevated in the range associated with clinical manifestations of <info type="DiseaseOrPhenotypicFeature">central nervous system excitation</info>. No other risk factors for <info type="DiseaseOrPhenotypicFeature">CNS toxicity</info> were identified. This method allowed frequent self-dosing of <info type="ChemicalEntity">pethidine</info> at short time intervals and rapid accumulation of <info type="ChemicalEntity">pethidine</info> and <info type="ChemicalEntity">norpethidine</info>. The routine use of <info type="ChemicalEntity">pethidine</info> via PCA even for a brief <info type="DiseaseOrPhenotypicFeature">postoperative analgesia</info> should be reconsidered.